within Pharmacolibrary.Drugs.ATC.R;

model R03BB06
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00085,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.376,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 1.64,
    k12             = 63.7,
    k21             = 63.7
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03BB06</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Glycopyrronium bromide is a long-acting muscarinic antagonist (LAMA) used as a bronchodilator for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It acts by inhibiting acetylcholine at muscarinic receptors in the airway smooth muscle, resulting in bronchodilation. It is approved and widely used today in inhalation form for COPD.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters obtained from healthy adult subjects following single and multiple inhaled doses of glycopyrronium bromide (in the form of glycopyrronium bromide inhalation powder 50 mcg).</p><h4>References</h4><ol><li><p>Sechaud, R, et al., &amp; Hou, J (2016). Pharmacokinetics of Glycopyrronium Following Repeated Once-Daily Inhalation in Healthy Chinese Subjects. <i>European journal of drug metabolism and pharmacokinetics</i> 41(6) 723–731. DOI:<a href=&quot;https://doi.org/10.1007/s13318-015-0300-7&quot;>10.1007/s13318-015-0300-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26428357/&quot;>https://pubmed.ncbi.nlm.nih.gov/26428357</a></p></li><li><p>Rony, F, et al., &amp; Klein, J (2024). Evaluating the pharmacokinetics of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurised metered-dose inhaler using a low global warming potential propellant. <i>Pulmonary pharmacology &amp; therapeutics</i> 85 102299–None. DOI:<a href=&quot;https://doi.org/10.1016/j.pupt.2024.102299&quot;>10.1016/j.pupt.2024.102299</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38663512/&quot;>https://pubmed.ncbi.nlm.nih.gov/38663512</a></p></li><li><p>Kuna, P, et al., &amp; Ciurlia, G (2022). Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma. <i>Pharmacology research &amp; perspectives</i> 10(4) e980–None. DOI:<a href=&quot;https://doi.org/10.1002/prp2.980&quot;>10.1002/prp2.980</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35733414/&quot;>https://pubmed.ncbi.nlm.nih.gov/35733414</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03BB06;
